New insider Leoni Mollie claimed ownership of 46,966 shares (SEC Form 3)
$KURA
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/02/2025 |
3. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 46,966(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Option to purchase common stock | (2) | 02/09/2030 | Common Stock | 52,500 | $12.22 | D | |
| Option to purchase common stock | (3) | 01/25/2031 | Common Stock | 22,260 | $32.8 | D | |
| Option to purchase common stock | (4) | 01/25/2032 | Common Stock | 52,500 | $14.15 | D | |
| Option to purchase common stock | (5) | 02/15/2033 | Common Stock | 63,750 | $11.99 | D | |
| Option to purchase common stock | (6) | 07/02/2033 | Common Stock | 40,000 | $10.6 | D | |
| Option to purchase common stock | (7) | 01/01/2034 | Common Stock | 50,000 | $15.36 | D | |
| Explanation of Responses: |
| 1. Includes 4,716 shares of common stock and 42,250 shares of common stock that may be issued pursuant to the following restricted stock unit awards (RSUs): (i) 1,781 shares pursuant to a RSU granted on 1/26/21 that will vest on 1/26/25, (ii) 7,500 shares pursuant to a RSU granted on 1/26/22 that will vest in equal installments on 1/26/25 and 1/26/26,(iii) 7,969 shares pursuant to a RSU granted on 2/16/23 that will vest in equal installments on 1/26/25, 1/26/26 and 1/26/27, and (iv) 25,000 shares pursuant to a RSU granted on 1/2/24 that will vest in equal installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28. |
| 2. Fully Vested |
| 3. This option vests in 48 equal monthly installments commencing on the grant date of 1/26/21. |
| 4. This option vests in 48 equal monthly installments commencing on the grant date of 1/26/22. |
| 5. This option vests in 48 equal monthly installments commencing on the grant date of 2/16/23. |
| 6. This option vests in 48 equal monthly installments commencing on the grant date of 7/3/23. |
| 7. This option vests in 48 equal monthly installments commencing on the grant date of 1/2/24. |
| Teresa Bair, Attorney-in-fact for Mollie Leoni | 01/07/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||